{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:50:55Z","timestamp":1791575455698,"version":"4.3.4"},"reference-count":55,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To identify patterns of opioid analgesic use and determine predictors of persistent opioid use among people without cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A population\u2010based cohort study of Australians initiating prescription opioids from July 2013 to December 2015 was conducted using data from a random 10% sample of people who accessed medicines through Australia's Pharmaceutical Benefits Scheme. A 12\u2010month retrospective period was used to define opioid initiation, exclude people with cancer and determine comorbidities. Persistent use over 12 months since initiation was identified through group\u2010based trajectory modelling. Odds ratios (OR) and 95% confidence intervals (CIs) for predictors of opioid persistence were estimated using logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort consisted of 431\u2009963 people without cancer who initiated opioids. A total of 11\u2009323 (2.6%) persistent opioid users were identified. Predictors of persistence included initiation with transdermal formulations (OR 4.2, 95% CI 3.9\u20134.5), or initiation with total oral morphine equivalents (OME) \u2265 750\u00a0mg (3.7, 3.3\u20134.1), having depression (1.6, 1.5\u20131.7) or psychotic illness (2.0, 1.9\u20132.2). Previous dispensing of paracetamol (2.0, 1.9\u20132.1), pregabalin (2.0, 1.8\u20132.1) and benzodiazepines (1.53, 1.4\u20131.6) predicted persistence. Compared to people aged 18\u201344 years, those \u226575 years were 2.5 (2.3\u20132.6) times more likely to be persistent users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patient\u2010specific characteristics (older age, prior history of mental health comorbidities and use of non\u2010opioid analgesics) and prescriber choice of initial opioid (transdermal formulation and higher total OMEs) were found to strongly predict persistent use. This information may help prescribers target monitoring and early intervention efforts in order to prevent harms associated with the long\u2010term use of opioids.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13556","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T13:52:58Z","timestamp":1518789178000},"page":"1267-1278","source":"Crossref","is-referenced-by-count":67,"title":["Predictors of persistent prescription opioid analgesic use among people without cancer in Australia"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7055-3626","authenticated-orcid":false,"given":"Samanta","family":"Lalic","sequence":"first","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Melbourne Australia"},{"name":"Pharmacy Department Austin Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Gisev","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon","family":"Bell","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit Jaana","family":"Korhonen","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Ilom\u00e4ki","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-770"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12050"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-6405.2010.00519.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170363"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.008"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00161-6"},{"key":"e_1_2_9_8_1","unstructured":"Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes. New York: United Nations 2015 [online]. Available at:http:\/\/www.incb.org\/documents\/Publications\/AnnualReports\/AR2015\/English\/Supplement\u2010AR15_availability_English.pdf(last accessed 7 January 2018)."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000738"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090784"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.36076\/ppj\/2019.19.215"},{"key":"e_1_2_9_12_1","article-title":"A review of potential adverse effects of long\u2010term opioid therapy: a practitioner's guide","volume":"14","author":"Baldini A","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2559"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6610a1"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000730"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/AJP.0000000000000409","article-title":"A prospective study of predictors of long\u2010term opioid use among patients with chronic noncancer pain","volume":"33","author":"Thielke SM","year":"2017","journal-title":"Clin J Pain"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.01.011"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080095"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_2_9_20_1","unstructured":"Australian Statistics on Medicines 2011. Canberra: Australian Government Department of Health 2013[online]. Available athttp:\/\/www.pbs.gov.au\/info\/statistics\/asm\/asm\u20102011(last accessed 10 January 2018)."},{"key":"e_1_2_9_21_1","unstructured":"About the PBS. Canberra: Australian Government Department of Health 2017[online]. Available athttp:\/\/www.pbs.gov.au\/info\/about\u2010the\u2010pbs(last accessed 11 January 2018)."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4329"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.4.2.139"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.clinpsy.121208.131413"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2011.00018.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.03.016"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2017.04.002"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(95)00017-M"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3945"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000064641.84967.B7"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.02.015"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760"},{"key":"e_1_2_9_33_1","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2010\u20132014","volume":"65","author":"Warner M","year":"2016","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.05.005"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000298474"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.20.2433"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2017.04.004"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.05.010"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03052.x"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.12.012"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12024-014-9624-x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12033"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_2_9_44_1","unstructured":"Analgesic Expert Group.Chronic pain: pharmacological management. Therapeutic guidelines: analgesics. Melbourne 2012[online]. Available athttps:\/\/www.tg.org.au\/(last accessed 11 January 2018)."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja15.00174"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1251"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010664"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000021"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12773"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1034095"},{"key":"e_1_2_9_51_1","unstructured":"Australian Bureau of Statistics.Facts at your fingertips: Health 2011. Characteristics of bodily pain in Australia. Canberra: Australian Bureau of Statistics 2012 [online]. Available athttp:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/Lookup\/4841.0Chapter12011(last accessed 11 January 2018)."},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0690(05)70078-1"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00355-9"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.j.pain.0000460303.63948.8e"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000218804.41758.ef"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-6405.2009.00357.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13556","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T06:43:08Z","timestamp":1695019388000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,2]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/bcp.13556"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13556","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,2]]}}}